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ciﬁc oligonucleotide primed PCR (PCR-SSO). Both methods
showed a homozygous phenotype for HLA class I loci (A, B, C)
and heterozygosity for HLA class II alleles (DRB1,DQB1). After
consolidation, increasing minimal residual disease (MRD)
measured by a close NPM1, monitoring was observed in
September 2013 and the patient was scheduled for an allo-
geneic stem cell transplantation. No blasts were present in
the peripheral blood of the patient at the time point of mo-
lecular relapse. To initiate search for an unrelated donor a
conﬁrmatory patient HLA-typing was performed. Due to
poor S2 DNA quality a new blood sample (S3) was ordered
and used for secondary typing. Whereas HLA class II results
were consistent, SBT and PCR-SSO showed discrepant class I
typing results when compared to S1, with heterozygosity for
all three loci. Consultation of the transplantation center
revealed that S1 + S2 were taken while the patient had 84%
blasts in the peripheral blood. Heterozygous patient HLA
status was ﬁnally conﬁrmed by typing of a saliva sample (S4)
with SBT and SSO-PCR, respectively. According to the infor-
mation about S1 (primary diagnosis, peripheral blasts), S3
(increasing MRD, no peripheral blasts) and S4 (blast free
material) we assumed that in S1 cells with somatic HLA class
I phenotype were highly outnumbered by blasts bearing a
complete class I LOH.
In regard to this casewestrongly recommend conﬁrmatory
typing to be carried out on blast free samples only, or by using
a highly sensitive PCR-SSP in case of a substantial amount of
blasts in the blood. This should help to prevent the otherwise
potentially fatal selection of a highly mismatched donor. As a
consequence we established a routinely feedback on the pe-
ripheral blast status of the sample on our test request form.IMMUNE RECONSTITUTION
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Background: CD34+ and CD3 cell-doses given during autol-
ogous stem cell transplantation (ASCT) can vary between
patients (pts) depending on ability to mobilize and cell
collection method. Retrospective studies suggest that im-
mune recovery and absolute lymphocyte count (ALC) may be
a predictor of overall survival (OS), progression free survival
(PFS), and infectious complications in ASCT. However, It is
unclear whether there is an optimal CD34+ or CD3 cell-dose
that correlates with better outcomes.
Methods: A retrospective analysis of the immune recovery
was performed on 24 consecutive lymphoma pts who had
undergone ASCT from 1/2012 to 6/2014 at the University of
Virginia to determine if a relationship existed between
CD34+ or CD3 cell-dose given during ASCT and immune re-
covery. For each pt, number/type of infections, IgG level, T
cell counts (CD4 and CD8), and ALC were collected for the
ﬁrst 100 days post-ASCT. OS and PFS were also assessed for
each pt. Cox proportional hazard models were used to esti-
mate the association of cell-dose infused with time to count
recovery after ASCT.Results: Median age was 57 years (range from 28-69 years),
and 62% were male. Lymphoma subtypes were 62% B cell
lymphoma, 21% Hodgkin and 17% systemic T cell. All Pts were
with advance stages and heavily pretreated (median 2 lines).
Peripheral blood stem cell grafts had a median CD34 of
6.2x10
ˇ
6, TNC of 10.9 x10
ˇ
8, and T cells of 154 x10
ˇ
6. Almost
half of the pts (n¼11) were mobilized with plerixafor with no
chemotherapy.Median followupwas 417days (102-763). The
analysis revealed that a higher CD34+ cell-dose given was
signiﬁcantly (p<0.05) associated with higher IgG at day 30
and earlier platelet recovery (>50,000). Higher T cell dose
(>150x106) was also associated with higher IgG level at day
30, but unlike CD34dose, CD3was associatedwith higherALC
(>1000 cells/microL) at day 100 (p<0.05). Due to sample size
and different disease associated risk factors, effect of cells
dose on relapsewas not statistically signiﬁcant. Infection rate
(almost half of pts) was similar in high vs. low cell dose. Most
of the infections were bacterial and happened early post
transplant with the exception of two cases of inﬂuenza and
CMV. Pts who were mobilized with plerixafor without
chemotherapy had a higher dose of CD3 collected compare to
pts mobilized with chemotherapy (239 vs. 113. P¼0.056).
Conclusion: These preliminary results suggest that CD3+
cell-dose > 150x106 cells/kg given during ASCT for aggres-
sive lymphoma may be associated with not only better early
IgG level and but also with better ALC. However, larger
prospective trials are necessary to further deﬁne optimal CD3
and CD34+ cell-dose infusion for ASCT in lymphoma pts in
order to improve immune recovery and prevent relapse.200
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Introduction: Bacterial bloodstream infections (BBSIs)
contribute signiﬁcantly to transplant relatedmortality (TRM)
post allogeneic hematopoietic cell transplant (alloHCT). In
2006, a new central-line associated bloodstream infection
(CLABSI) protocol was established at our institution. We
report the incidence rate and sensitivities of both Gram
negative rod (GNR) and Gram positive cocci (GPC) BBSIs
during Pre-CLABSI era (2004-06), CLABSI era (2006-10), and
post-CLABSI era (2010-13).
Methods: A retrospective chart review between 2004-2013
was conducted. 100 person-month bacterial infection
incidences were calculated and compared by Poisson
regression analysis. Patients did not receive prophylactic
anti-bacterial antibiotics and piperacillin/tazobactam was
started at the onset of fever.
Results: Between 2004-13, 302 BBSIs were identiﬁed in 190
patients (mean age 9.97 years). Malignant 111 (58.4%), Non-
malignant 79 (41.6%); donor source: Marrow 71 (37.4%), Pe-
ripheral Blood Stem Cell 59 (31.1%), Cord blood 60 (31.5%).
Conditioning regimens: myeloablative¼ 86 (45.3%), reduced
Table 1
2004-06 2006-10 2010-13 p (2004-06 vs
2010-13)
Day 0 to +30 42.1% 33.4% 13.8% 0.016
Day +31 to +100 61.9% 30.5% 12.7% <0.001
Day +101 to +180 62.4% 45.7% 19.8% 0.001
Day +181 to +365 26.3% 19.9% 5.0% <0.001
Figure 1. HCV Quantitative RNA PCR HCV viral load in peripheral blood was
monitored by quantitative PCR for HCV RNA weekly. Patient had 7 log10 titer
prior and after UCBT. Titers decreasedw2 log10 fold weekly after initiation of
treatment.
Abstracts / Biol Blood Marrow Transplant 21 (2015) S147eS170 S163toxicity¼ 57 (30%), reduced intensity¼ 47 (24.7%); incidence
of neutrophil engraftment by day +30 was 82%, and inci-
dence of grade II-IV aGVHD was 44.2%,
For the different time periods of immune reconstitution,
the rate per 100 person months of bacterial infections
decreased as shown in table 1. Of the BBSIs for each time
period, the proportion of GPC BBSIs decreased (2004-06:56%,
2006-10:53.1%, 2010-13:39.2%, respectively), 2004-06 vs.
2010-13, p¼0.048.
GNR antibiotic resistance increased to levoﬂoxacin (4.4%
from 2004-06 to 17.2% from 2010-2013), decreased to cefe-
pime (13.3% from 2004-06 to 7.7% from 2010-13), and
remained stable to piperacillin-tazobactam (7.7% in 2004-06
to 9.1% from 2010-13). GPC antibiotic resistance to vanco-
mycin increased from 3.4% in 2004-06 to 10.5% in 2010-13.
Lastly, in our multivariate analysis RTC regimen was a
signiﬁcant risk factor for the development of piperacillin-
tazobactam resistance in GNR (OR 4.421, 95% CI 1.331-14.69,
p¼0.015). TRM was signiﬁcantly higher in BBSI patient be-
tween 2004-06 (27.9%) vs. 2010-13 (9.3%) (p¼0.03).
Discussion: Our analysis showed a decrease in BBSI rates
after CLABSI protocol was implemented at our institution
and a signiﬁcant decline in BBSI in the post-CLABSI era. The
proportion of GPC infections decreased over this time period.
However, further investigation on factors associated with
decrease in BBSI in these different time periods is ongoing.
The rise in vancomycin resistance (likely due to its wide-
spread use as empiric antibiotic choice for alloHCT patients
with fever), warrants further investigation.201
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Hepatitis C virus (HCV) infection increases the non-relapse
mortality risk after HSCT. Oral direct-acting antiviral (DAA)
drugs Simeprevir, an NS3/4A protease inhibitor, in combi-
nation with Sofosbuvir, a nucleotide analogue inhibitor of
NS5G polymerase are replacing the standard therapy of
interferon (IFN) and ribavirin (RBV). Here, we present the
ﬁrst case report of a pediatric patient with very high HCV
viral load after an UCBTwhowas treatedwith Sofosbuvir and
Simeprevir. The patient had an early virologic response (EVR)
and developed HCV-speciﬁc CD3+ T cells.
A 4 yr. old girl was referred for relapsed B-lymphoblastic
leukemia in CR3. HCV antibody was negative but nucleic acid
test was positive. HCV RNA PCR was elevated at log 7.2 (Fig1). Genotype was HCV-1a subtype with unfavorable vari-
ants for IL28BS but NS3 genotype was negative. Liver US was
normal and LFT was not signiﬁcantly elevated. Liver biopsy
was negative for ﬁbrosis and cirrhosis but demonstrated
moderate hepatitis.
Patient underwent a single 4 of 6 UCBT (10.6 x107 TNC/kg)
using TBI, ﬂudarabine and cyclophosphamide. GVHD pro-
phylaxis included cyclosporine (CSA) and mycophenolate
mofetil (MMF). Engraftment occurred on D13. Sinusoidal
obstruction syndrome (SOS) developed on D20-33 and
treatedwith deﬁbrotide. HCV treatment was initiated on D75
with Sofosbuvir and Simeprevir. Weekly PCR for HCV RNA
demonstrated w2log decrease (Fig 1) despite remaining on
CSA. Viral speciﬁc immune response to HCV was evaluated
using donor speciﬁc HLA-A restricted tetramer. The patient
was HLA-A*32:01/30:02 and received an UCB with HLA-
A*3:01/30:01. Using HLA-A*03:01 restricted tetrameter for
HCV epitope KLVALGINA, we identiﬁed HCV speciﬁc donor T
cells. CDR3 regions are being sequenced to determine
whether the T cell response is oligoclonal or polyclonal. The
availability of the new, highly effective oral DAA HCV medi-
cation allows for IFN-free therapy and will impact the
treatment for HCV after HSCT. The ability to clear the HCV
and maintain viral remission will signiﬁcantly decrease the
risk of developing cirrhosis, hepatic failure and hepatocel-
lular carcinoma.202
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Background: Despite advances in novel anti-plasma cell
therapies translating to improved outcomes, multiple
